Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.
Applying for disability benefits is complicated. Blogger Trevis Gleason encourages people with multiple sclerosis to reach out to friends with MS for help with navigating the process.
A review of a disability benefit is not expected to make "crude proposals" on changes to claimants' payments, the minister ...
Nanocurcumin was linked to better disability scores in small RRMS trials, but researchers say larger studies are needed.
Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study, showing that Microsoft (MS) ...
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant ...
Cenrifki represents a significant advancement for people living with SPMS by targeting disability progression Approval based on the HERCULES phase 3 study in nrSPMS with supporting data from the ...
BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with ...
The proportion of patients with 12-week composite confirmed disability progression was 33 and 40%, respectively, with ocrelizumab and placebo. HealthDay News — For patients with primary progressive ...
Having a second autoimmune disease does not speed up multiple sclerosis disability progression. Multiple sclerosis patients with another autoimmune condition reached disability milestones at the same ...
In people with primary progressive multiple sclerosis (PPMS), depressive symptoms measured using the Hospital Anxiety and Depression Scale (HADS) predicted subsequent neurologic disability progression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results